Topical compositions
The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.
1. A topical gel formulation comprising:
1-1.5 wt. % clindamycin phosphate;
2.5-3.5 wt. % benzoyl peroxide;
about 0.15-0.2 wt. % adapalene;
a gelling agent;
a polyhydric alcohol; and
water,
wherein the gelling agent is selected from the group consisting of hydroxypropylcellulose, hydroxyethylcellulose, carboxyvinyl polymers, carboxyvinyl polymers crosslinked with allyl ethers of polyalcohols, carboxyvinyl copolymers, polyacrylates, acrylate copolymers, acrylamide/sodium acryloyldimethyltaurate copolymers, polyvinyl alcohols, polyethylene oxides, propylene glycol alginates, methylcellulose, hydroxypropylmethylcellulose, xanthan gum, carrageenan gum, and combinations thereof.
2. The formulation of claim 1 , wherein the topical gel formulation has about 1.2 wt. % clindamycin phosphate, about 3.1 wt. % benzoyl peroxide, and about 0.15 wt. % adapalene.
3. The formulation of claim 2 , wherein the formulation comprises
a) about 1.2 wt. % clindamycin phosphate,
b) about 3.1 wt. % benzoyl peroxide,
c) about 0.15 wt. % adapalene,
d) about 5 wt. % propylene glycol,
e) about 1.75 wt. % carbomer homopolymer Type C,
f) potassium hydroxide in an amount to provide a pH of 5-6, and
g) water.
4. A method of treating an inflammatory skin condition in a patient in need thereof, comprising administering to an affected area of the skin on at least a daily basis, a topical gel formulation according to claim 1 .
5. The method of claim 4 , wherein the inflammatory skin condition is acne.
6. The method of claim 5 , wherein administration is once daily over a period of at least 4 weeks.
7. The method of claim 6 , wherein the treatment is more effective in treating acne than treatment with another formulation comprising active ingredients selected from the group consisting of (i) 1-1.5 wt. % clindamycin phosphate and 2.5-3.5 wt. % benzoyl peroxide, (ii) 2.5-3.5 wt. % benzoyl peroxide and 0.1-0.2 wt. % adapalene, and (iii) 1-1.5 wt. % clindamycin phosphate and 0.1-0.2 wt. % adapalene.
8. A drug container, comprising a pump and a topical gel formulation according to claim 1 , wherein the pump is calibrated to release a specific amount of the formulation each time the pump is pressed.
9. A method of making a topical gel formulation according to claim 1 , comprising
i) providing the following premixes:
a) Premix A comprising a dispersion of gelling agent in water,
b) Premix B comprising a dispersion of benzoyl peroxide in polyhydric alcohol and water,
c) Premix C comprising clindamycin phosphate in aqueous solution,
d) Premix D comprising a dispersion of micronized adapalene in polyhydric alcohol and water,
ii) mixing Premix A and Premix D,
iii) admixing Premix B to the mixture of step ii,
iv) admixing Premix C to the mixture of step iii, and
v) adjusting the pH of the mixture of step iv to pH 5-6 to form a gel.
10. The formulation of claim 1 , wherein the gelling agent comprises carbomer homopolymer Type C.
11. The formulation of claim 1 , wherein the gelling agent is a crosslinked polymer comprising carboxy moieties and wherein the formulation further comprises a base selected from the group consisting of potassium hydroxide, sodium hydroxide and combinations thereof in an amount sufficient to deprotonate the carboxy moieties sufficiently to cause the gelling agent to thicken.
12. The formulation of claim 1 , wherein the amount of gelling agent is 1.5-2 wt. %.
13. The formulation of claim 1 , wherein a fraction of the benzoyl peroxide is undissolved, wherein the undissolved fraction of the benzoyl peroxide is homogeneously dispersed in the formulation, and wherein the undissolved fraction of the benzoyl peroxide has a mean particle size between 1 and 50 microns.
14. The formulation of claim 13 , wherein a fraction of the adapalene is undissolved and wherein the undissolved fraction of the adapalene is homogeneously dispersed in the formulation.
15. The formulation of claim 1 , wherein the adapalene and the benzoyl peroxide do not undergo any oxidation reaction with one another.
16. The formulation of claim 1 , wherein the polyhydric alcohol is propylene glycol, ethoxydiglycol, polyethylene glycol, glycerol, or combinations thereof.
17. The formulation of claim 1 , wherein the formulation is free of additional agents as organic solvents other than the polyhydric alcohol.
18. The formulation of claim 1 , wherein the amount of polyhydric alcohol is 3-7 wt. %.
19. The formulation of claim 1 , wherein the formulation is free of ionic surfactants.